Description: NIHR Global Health Research Group on warfarin anticoagulation in patients with cardiovascular disease in Sub-Saharan Africa (War-PATH)
research (8551) study (1557) cardiovascular (248) clinical trial (171) warpath (6)
NIHR Global Health Research Group on warfarin anticoagulation in patients with cardiovascular disease in Sub-Saharan Africa (War-PATH)
The WarPATH NIHR Global Research Group is a study between the University of Liverpool, Infectious Diseases Institute, Uganda and University of Cape Town, South Africa. It will focus on a clinically important non-communicable disease area which requires the use of anticoagulation. Anticoagulants, in particular warfarin, are used in these countries for the treatment of venous thromboembolism, rheumatic heart disease and prevention of strokes in patients with irregular heart rhythms (atrial fibrillation).Doses
Anticoagulation with warfarin is an important area of unmet medical need in African countries because of the lack of validated dosing algorithms and/or monitoring facilities. We have extensive expertise in the UK and EU of improving the use of warfarin through the development of novel dosing algorithms, which have now began incorporating genetic factors. This group aims to improve anticoagulation by developing clinical dosing algorithms, and further improve anticoagulation quality by using novel technologic